We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
VistaGen Sees Promise for Stem Cell Breakthrough to Accelerate Drug Discovery and Development
News

VistaGen Sees Promise for Stem Cell Breakthrough to Accelerate Drug Discovery and Development

VistaGen Sees Promise for Stem Cell Breakthrough to Accelerate Drug Discovery and Development
News

VistaGen Sees Promise for Stem Cell Breakthrough to Accelerate Drug Discovery and Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "VistaGen Sees Promise for Stem Cell Breakthrough to Accelerate Drug Discovery and Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

VistaGen Therapeutics, Inc. welcomes news of the technological discovery reported last week that reprograms adult skin cells into human universal cells, according to H. Ralph Snodgrass, Ph.D., president and CEO.

VistaGen is a platform-enabled biopharmaceutical company applying embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders.

“This is very positive news both for our company and our industry,” said Dr. Snodgrass.

“Any new discovery or technology that enables the generation of diverse embryonic stem cells, especially those unique to specific diseases, is very useful. Our technologies enable us to differentiate embryonic stem cells into mature cells for leading-edge customized drug discovery and screening assays. We anticipate that this advancement should be able to complement our existing technologies by enabling us to focus with greater efficiency on specific genetic diseases, and on drugs that are safe and effective for a genetically diverse patient population.”

The discovery, reported both by James A. Thomson, the University of Wisconsin researcher who extracted stem cells from human embryos originally, and by Shinya Yamanaka of Kyoto University, showed that adult skin cells can be reprogrammed to mimic embryonic stem cells by adding four genes. The genes reprogrammed the chromosomes of the skin cells, making the cells into blank slates that should be able to turn into any of the 220 cell types of the human body, such as heart, brain, blood or bone.

Advertisement